N
Nicola P. Klein
Researcher at Kaiser Permanente
Publications - 292
Citations - 10778
Nicola P. Klein is an academic researcher from Kaiser Permanente. The author has contributed to research in topics: Vaccination & Medicine. The author has an hindex of 44, co-authored 234 publications receiving 6652 citations. Previous affiliations of Nicola P. Klein include Marshfield Clinic.
Papers
More filters
Journal ArticleDOI
Absence of venous thromboembolism risk following quadrivalent human papillomavirus vaccination, Vaccine Safety Datalink, 2008-2011.
Allison L. Naleway,Brad Crane,Ning Smith,Matthew F. Daley,James G. Donahue,Julianne Gee,Sharon K. Greene,Theresa Harrington,Lisa A. Jackson,Nicola P. Klein,Hung Fu Tseng,Claudia Vellozzi,Eric Weintraub +12 more
TL;DR: The risk of developing VTE among 9- to 26-year-olds was not elevated following HPV4 exposure and the ability to rigorously evaluate potential effect modifiers, such as gender, through stratified analysis was limited.
Journal ArticleDOI
Lot-to-lot consistency, safety, tolerability and immunogenicity of an investigational hexavalent vaccine in US infants
Stanley L. Block,Nicola P. Klein,Kwabena O. Sarpong,Stephen Russell,John A. Fling,Maria Petrecz,Sheryl A. Flores,Jin Xu,Guanghan Liu,Jon E. Stek,Ginamarie Foglia,Andrew W. Lee +11 more
TL;DR: HV demonstrated lot-to-lot manufacturing consistency; safety and immunogenicity were comparable with the licensed vaccines; HV provides a new combination vaccine option within the US 2-month, 4-month and 6-month vaccine series.
Journal ArticleDOI
Asthma exacerbations among asthmatic children receiving live attenuated versus inactivated influenza vaccines.
G. Thomas Ray,Ned Lewis,Kristin Goddard,Pat Ross,Jonathan Duffy,Frank DeStefano,Roger Baxter,Nicola P. Klein +7 more
TL;DR: Among children ≥2years old with asthma, there is no increased risk of asthma exacerbation following LAIV or IIV, and a decreased risk followingLAIV compared to IIV.
Journal ArticleDOI
Risk of myocarditis and pericarditis following BNT162b2 and mRNA-1273 COVID-19 vaccination
Kristin Goddard,Ned Lewis,Bruce Fireman,Eric Weintraub,Tom T. Shimabukuro,Ousseny Zerbo,Thomas G. Boyce,Matthew E. Oster,Kayla E. Hanson,James G. Donahue,Pat Ross,Allison L. Naleway,Jennifer C. Nelson,Bruno Lewin,Jason M. Glanz,Joshua T B Williams,Elyse O. Kharbanda,W. Katherine Yih,Nicola P. Klein +18 more
TL;DR: Both vaccines were associated with increased risk of myocarditis and pericarditis in 18-39-year-olds and head-to-head comparisons 0–7 days after either dose, risk was moderately higher after mRNA-1273 than after BNT162b2.
Journal ArticleDOI
Vaccine Safety Datalink infrastructure enhancements for evaluating the safety of maternal vaccination.
Allison L. Naleway,Bradley Crane,Stephanie A. Irving,Don Bachman,Kimberly K Vesco,Matthew F. Daley,Darios Getahun,Sungching C. Glenn,Simon J. Hambidge,Lisa A. Jackson,Nicola P. Klein,Natalie L. McCarthy,David L. McClure,Lakshmi Panagiotakopoulos,Catherine A. Panozzo,Gabriela Vazquez-Benitez,Eric Weintraub,Ousseny Zerbo,Elyse O. Kharbanda +18 more
TL;DR: In this article, identifying pregnancy episodes and accurately estimating their beginning and end dates are imperative for observational maternal vaccine safety studies using electronic health record (EHR) using EHRs.